Articles tagged with T Cell Activation
A study by UCLA Health researchers linked low immune responses to higher mortality rates in patients, using tuberculosis screening tests as a tool. The results suggest that these tests can predict mortality in various patient groups, including those undergoing organ transplants and cancer patients on immunotherapy.
A new study reveals that impaired protein recycling is the key factor in T cell exhaustion, allowing researchers to develop a 'tag and sort' fix to restore normal proteostasis. This approach boosts the potency of cell therapy against cancer.
A study by University of Pittsburgh researchers found that eating creates a temporary metabolic state that influences T cell function, leading to improved responses to infection. The findings have particular relevance for cancer immunotherapy and may inform when immune cells are collected or activated.
Researchers found memory cells in nasal tissue can reactivate to fight influenza, reducing viral replication and protection against more severe illness. These immune cells can be used to develop better nasal vaccines.
A multi-institutional team has discovered a novel immune regulatory mechanism mediated by antibodies that selectively shut down overactive immune responses. The 'immune-induced TCR-like antibody' (iTab) can reduce disease severity and delay its onset in a mouse model of autoimmune disease.
Researchers developed a method to rapidly assess T cell viability, activation state, and subtype without fluorescent labels or cell destruction. The approach uses static and dynamic deep-UV imaging to achieve high accuracy in classifying T cells into three categories: activated, dead, and quiescent.
A study found significant CD39 expression on CD4+ T-cells in HIV/HCV coinfected patients, with a negative correlation between CD39 positivity and pro-inflammatory chemokines. This suggests that CD39-positive T-cells play a role in controlling purinergic signaling in these patients.
Researchers at Salk Institute uncover two transcription factors, ZSCAN20 and JDP2, that determine T cell fate. Turning off these genes reverses T cell exhaustion and restores their ability to kill tumors without losing immune memory. The study challenges the long-standing belief of inevitable immune exhaustion.
Researchers at Johns Hopkins Medicine report a significant reduction in HIV-infected CD4+ T immune cells after chemotherapy treatment. This finding may be an early step toward a more practical HIV cure, as the virus relies on frequent proliferation to persist in the body.
Researchers at La Jolla Institute for Immunology discovered that ALS is likely caused by an autoimmune reaction triggered by inflammatory CD4+ T cells targeting specific proteins in the nervous system. Anti-inflammatory CD4+ T cells may slow disease progression and prolong survival times.
Researchers engineered CAR T cells to produce a fusion of IL-12 cytokine and a PD-L1 blocker, boosting immune activity against solid tumors. The modified cells were found to be highly effective in shrinking ovarian and prostate tumors while minimizing side effects.
Researchers are developing a novel smart coating to enable continuous monitoring of cells during CAR T-cell production, reducing production costs. The biosensor coating is expected to reduce human errors and costs associated with existing flow cytometry methods.
Researchers discovered a multi-faceted mechanism behind ASD, revealing the gut microbiota and host immune system's influence on disease progression. Precision-selected probiotics restored metabolic balance, reduced neuroinflammation, and ameliorated behavioral abnormalities in ASD mouse models.
Researchers found that HPV16 undermines the body's defenses by reprogramming immune cells surrounding tumors. Blocking IL-23 boosts experimental treatments for HPV to eliminate cancer cells.
Conventional dendritic cells have been found to originate from both myeloid and lymphoid progenitors, revealing their unique functions and developmental pathways. These lymphoid-derived cDCs exhibit potent functions in immune suppression and allergy induction, and follow diverse developmental pathways.
Recent advancements have identified several immunomodulators with promising roles in AIH treatment, including MMF, tacrolimus, sirolimus, infliximab, rituximab, and belimumab. These agents target specific immune pathways and have shown efficacy in achieving biochemical and histological remission.
Researchers have developed a novel treatment approach for autoimmune diseases by engineering a protein that holds closely together two signaling complexes on T cells, shutting down those T cells in a limited way. This approach shows promise for treating conditions such as Type-1 diabetes and multiple sclerosis.
A UCLA study found that selective serotonin reuptake inhibitors (SSRIs) can significantly enhance the ability of T cells to fight cancer and suppress tumor growth across various cancer types in mouse and human tumor models. SSRIs increased access to serotonin signals, making killer T cells happier and more effective at killing cancer c...
A new study published in the Proceedings of the National Academy of Science demonstrates a critical enzyme pathway in maintaining immune cell activity. The research suggests that histone deacetylase (Hdac1) plays a crucial role in preventing excessive decline of effectiveness in exhausted cells.
A new study by Mass General Brigham researchers has identified a natural 'brake' within the innate immune system that can prevent organ transplant rejection. The discovery highlights a promising target for new therapies and offers hope for longer-lasting transplant success and reduced need for lifelong immunosuppression.
A new study by Johns Hopkins Medicine researchers has identified a protein called QRICH1 as a potential target for fine-tuning treatments for cancer and autoimmune diseases. The protein regulates T-cell response, and drugs could be designed to control its activity.
A recent study published in Cell revealed that a specific intestinal immune cell prevents food allergies by breaking the threshold between friend and foe in the gut. Researchers at WashU Medicine identified this cell as RORγt+ dendritic cells, which maintain tolerance to harmless food allergens, preventing allergic reactions.
Researchers found that aspirin prevents cancers from spreading by decreasing a clotting factor called thromboxane A2 and releasing T cells from suppression. This discovery could lead to the development of targeted treatments to prevent cancer metastasis, making aspirin potentially less expensive than antibody-based therapies.
Researchers at Osaka University developed a new technique called single-cell suppressive profiling of regulatory T cells (scSPOT) that can pinpoint the effects of Tregs on all other immune cells. The study found that Tregs most strongly affect CD8-EM T cells, which play a key role in fighting cancer and infections.
Researchers at the University of Melbourne have identified a rare type of immune cell, called stem-like T cells, that holds the key to maintaining powerful, long-term immune responses. ID3+ T cells have the remarkable ability to resist burnout and maintain a powerful immune response over time.
This study investigates the biological mechanisms underlying incomplete immune reconstitution and evaluates Dihydroartemisinin's potential as a therapeutic agent. DHA effectively inhibits T cell activation in individuals with incomplete immune reconstitution, presenting a promising treatment strategy.
Scientists at Salk Institute discovered that removing bile acid-creating protein BAAT and adding bile acid UDCA controls tumor growth in mice with liver cancer. UDCA supplements may be a quick solution to improving liver cancer patient outcomes.
A new study has identified macrophage activity as a key predictor of which skin cancer patients are most likely to respond to immunotherapy. The findings aim to improve personalized medicine for cancer patients and enable clinicians to select effective treatments, reducing side effects and costs.
Researchers at the University of Alabama at Birmingham have identified HIF1α as a key regulator that induces cancer-killing capacity in T cells under hypoxic conditions. In this study, they found that HIF1α-glycolysis is indispensable for IFN-γ induction in hypoxic T cells.
Researchers at Salk Institute establish a novel framework for the relationship between nutrition and cell identity. They found that a nutritional switch from acetate to citrate plays a key role in determining T cell fates, shifting them from active effector cells to exhausted cells.
Researchers at Gladstone Institutes and UCSF identified MED12 as a crucial switch that regulates T cell rest and activation. The study found that MED12 promotes rest in resting cells and activation in activated cells, and its removal led to blurred lines between rest and activation.
Researchers at Uppsala University have developed a unique antibody that targets and delivers a drug package while activating the immune system. This '3-in-1 design' method has shown promise in treating several types of cancer by amplifying T cell effect on cancer tumors.
Researchers found a surprising link between high levels of methylmalonic acid and the weakening of CD8+ T cells, shedding light on potential pathways through which aging may promote lung cancer progression. Elevated methylmalonic acid levels disrupt energy production in immune cells, making it harder for them to fight cancer.
Researchers from Osaka University discovered that the GPR31 receptor in gut surveillance cells detects bacterial metabolites and triggers immune responses, which could lead to new drug developments and probiotic treatments. The study also found that these receptors play a key role in the immune response to gut infections in humans.
A new study reveals a connection between NF-κB signaling pathways and X chromosome inactivation in T cells, which has implications for understanding sex-based immune responses. Researchers found that the maintenance of X chromosome inactivation depends on nuclear factor kappa B (NF-κB), a transcription factor.
Researchers found that neoself-antigens, presented on MHC-II, induce an immune response and lead to autoimmunity in lupus patients. EBV reactivation increases the presentation of these antigens, triggering T cell activation and autoimmune disease development.
A subset of CD4 T cells create an anti-inflammatory environment within the lung tissue, protecting against TB reinfection by limiting bacterial growth and disease severity. The discovery complements previous research on protective immune T cells in controlling TB infection, suggesting a potential key to improving existing vaccines.
Researchers have discovered that sodium chloride can increase the efficiency of antitumoral T cells, leading to improved metabolic fitness and enhanced tumor killing capabilities. This finding has significant implications for adoptive T-cell therapy in cancer treatment.
Researchers uncovered how combining immunotherapies targeting PD1 and LAG3 enhances CD8+ T cell responses, leading to improved cancer-killing prowess and enhanced survival rates. The studies also revealed that relatlimab is not inert and can be combined with other immunotherapies to improve responses.
A new index uses inflammatory cell proportions to predict tissue healing and outcomes in patients with ulcerative colitis. The index, called the inflammatory cell enumeration index (ICEI), was developed by analyzing data from 220 patients who achieved healing.
New research published in The FASEB Journal shows that blocking CTLA-4 activates Th17 cells, increasing inflammation and damaging the heart. Inhibiting this activation reverses anti-CTLA-4-mediated heart damage.
Researchers developed a drug that enhances killer T cells' fighting power while reducing the toxicity of unmodified IL-2 treatments, overcoming inhibitory Tr1 cells and increasing immunotherapy's effectiveness. The study aims to personalize cancer immunotherapy for more patients.
Researchers developed a lipid nanoparticle formulated miR-193a-3p mimic that enhances T cell mediated immune responses and induces immunogenic cell death in tumors. This study demonstrates the potential of this therapy to prolong animal survival and reduce metastasis, offering new hope for cancer treatment.
A new DNA-powered signal amplification technology called ACE significantly enhances the sensitivity of mass cytometry, enabling the detection of multiple proteins in single cells. This breakthrough allows researchers to investigate complex biological processes and study immune cell functions with unprecedented depth.
A novel strategy using venetoclax and azacitidine demonstrates significant anti-cancer effect with mild toxicity for relapsed/refractory AML patients. The treatment showed markedly better survival rates after one year compared to a control group, with improved 'graft-versus-leukemia effects' via alterations of immune cells.
Researchers explore various immunotherapies, including immune checkpoint inhibitors and adoptive cell therapies, as promising treatments for hepatocellular carcinoma. The review aims to overcome current limitations of targeted therapies by regulating the body's immune systems.
Researchers describe redundant innate immune pathways triggered by AAV vectors, including sensing of viral genome and cytoplasmic DNA sensors. The study highlights the need to understand complex biologic mechanisms underlying adverse reactions to AAV vectors in human gene therapy trials.
Researchers at University of Cambridge uncover unified healer army of regulatory T cells that constantly move and repair damaged tissue. This discovery has implications for treating various diseases, including autoimmune disorders and infectious diseases.
Researchers at Wyss Institute develop subcutaneous scaffolds to restimulate CAR-T cells, increasing therapeutic efficacy in mice with aggressive blood tumors. The biomaterials increase CAR-T cell numbers and steer differentiation into tumor-killing T cells.
Researchers created an artificial lymph node using hyaluronic acid, which connects with T-cells via a cell surface receptor. The noden acted as a learning hub, stimulating T-cells to recognize and kill cancer cells in mice with melanoma and colon cancers.
Researchers at Pohang University of Science & Technology have developed a method to boost bispecific antibody therapies in treating solid tumors. Using rhIL-7-hyFc, they found that bystander T cells can be activated by bispecific antibodies to destroy tumor cells, overcoming limitations of existing treatments.
A team of POSTECH and ImmunoBiome has discovered a dietary-derived bacterial strain, IMB001, that induces nutritional immunity and boosts anti-tumor responses. The strain works by skewing tumor-infiltrating macrophages toward an inflammatory phenotype, leading to increased cell death of rapidly multiplying tumor cells.
Researchers found that ARID1A mutation renders tumors sensitive to immunotherapy by triggering an antiviral immune response. This could lead to improved patient outcomes and the development of targeted therapies.
Researchers at La Jolla Institute for Immunology have developed a new, rapid method to study phosphorylation and other post-translational modifications in immune cells. This method sheds light on signaling pathways that trigger T cell activation and reveals how phosphate groups direct specific gene expression responses.
Researchers found that STAP-1 plays a crucial role in activating T cells, which are white blood cells critical to defending against infections and maintaining overall health. The study suggests that STAP-1 may be involved in the development of immune disorders such as multiple sclerosis and asthma.
A new type of cell therapy has shown promising results in improving survival rates and reducing pneumonia among critically ill ARDS patients recovering from severe Covid-19. The invariant natural killer T (iNKT) cell therapy, known as agenT-797, triggered an anti-inflammatory response and activated anti-viral immunity.
Researchers found that vaccinated B cell-deficient individuals have a robust T cell response to SARS-CoV-2, despite lack of anti-spike antibodies, resulting in markedly reduced rates of hospitalization and severe COVID-19. This study provides reassuring evidence for immunocompromised patients to get vaccinated.
Researchers discovered an alternative immune response involving NK and CD4+ T cells that can recognize and attack cancer cells when the usual recognition marker B2M is missing. This finding holds potential for developing more effective combination cancer immunotherapy treatments.
Researchers at UChicago find that trans-vaccenic acid (TVA), a fatty acid in meat and dairy, enhances CD8+ T cell immunity against tumors. TVA also improves response to immunotherapy treatments for patients with higher levels of the nutrient in their blood.
A research team from the University of California - Davis Health has identified a crucial epitope on the CD95 receptor that can trigger programmed cell death in cancer cells. This finding could lead to improved cancer treatments and potentially enhance CAR T-cell therapy for solid tumors like ovarian cancer.